Clinical Trial Update: An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS) [Phase 2]

View source ↗

Summary

Phase 2 extension study evaluating long-term safety and durability of LUM001 in Alagille Syndrome; trial completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alagille Syndrome

Drugs mentioned

• LUM001

Snippet

Sponsor: Mirum Pharmaceuticals, Inc. | Conditions: Alagille Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2021-11-19